New medical data reveals that silent atherosclerosis is present in more than half of healthy adults, including a significant portion of the young adult population.
A new clinical trial indicates that oral anticoagulants provide significant benefits for atrial fibrillation patients at an intermediate risk of stroke.
Sana Biotechnology is advancing a hypoimmune-modified cell therapy aiming for a functional cure for Type 1 diabetes without the need for immunosuppression.